Absci(US:ABSI) Globenewswireยท2025-11-12 21:05Core Insights - Absci Corporation is focusing on advancing its ABS-201 program for androgenetic alopecia and endometriosis, which are high-value indications with significant unmet medical needs [2][5][6] - The company reported interim results for its ABS-101 Phase 1 trial, showing an extended half-life compared to competitors and no serious adverse events [5][6] - Absci's financial position is strong, with sufficient cash and marketable securities to fund operations into the first half of 2028 [7][11] Pipeline Updates - The Phase 1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) is set to begin in December 2025, with an interim efficacy readout expected in the second half of 2026 [5][6] - The company plans to initiate a Phase 2 clinical trial for ABS-201 targeting endometriosis in Q4 2026, with a potential proof-of-concept readout in the second half of 2027 [6][7] - Absci is reallocating resources from ABS-101 to accelerate the development of ABS-201, reflecting a strategic shift towards indications with higher market potential [2][5] Financial Performance - For Q3 2025, Absci reported revenue of $0.4 million, a decrease from $1.7 million in Q3 2024 [8] - Research and development expenses increased to $19.2 million in Q3 2025 from $18.0 million in Q3 2024, driven by advancements in internal programs [9] - The net loss for Q3 2025 was $28.7 million, compared to a net loss of $27.4 million in Q3 2024 [10]